CONNECT WITH US
HealthTech

HealthTech

FDA clears Sequel’s insulin delivery system in Type 2 diabetes

MedTech Dive logo

Published on

Add as a preferred source on Google
FDA clears Sequel’s insulin delivery system in Type 2 diabetes

With Twiist already available in Type 1 diabetes, Sequel has made the automated insulin delivery system available for the Type 2 population.

Deka received clearance for the system in Type 1 diabetes in March 2024. Sequel launched the product nationally in the indication two years later. The latest clearance will enable immediate prescribing of the system for Type 2 diabetes patients, Sequel said.

The product’s algorithm is based on Tidepool Loop, a patient-led automated insulin dosing tool that received 510(k) clearance in 2023. Combining Deka drug delivery technology with the Loop algorithm positioned Sequel to compete for the AID market, initially in Type 1 diabetes.

Sequel disclosed the label expansion shortly after researchers published pivotal data on the system in Type 2 diabetes patients. Mean blood sugar fell from 8.1% at baseline to 7.4% after 13 weeks using the AID system. The percentage of time patients spent in the targeted blood sugar range increased from 57% to 73%.

Patients were more satisfied with the system than with their old insulin delivery method and reported improved sleep quality. Most patients had no experience with AID systems or carb counting at the start of the trial. Despite not being familiar with the technology, many patients experienced improved time in range within 24 hours of starting to use the AID system.

Clinical data show Twiist “can deliver the kind of burden-free improvement this community has long needed,” Joslin Diabetes Center’s Dr. Osama Hamdy said in a statement. The system adjusts basal insulin based on targets set by the user and their care team.


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.